Objective: This study aims to investigate the incidence, risk factors, and clinical characteristics of deep vein thrombosis (DVT) following radiofrequency ablation (RFA) combined with sclerotherapy for varicose veins. Methods: A retrospective analysis was conducted on patients who underwent combined RFA and sclerotherapy between June 2018 and June 2024. The incidence of postoperative DVT and its clinical characteristics were evaluated, with 13 potential risk factors assessed through univariate and multivariate logistic regression. Patients with distal DVT were divided into two groups: Group A (treatment with prophylactic-dose anticoagulation) and Group B (no anticoagulation), with thrombus resolution outcomes compared between the groups. Results: Among 567 patients with varicose veins, including 226 males and 341 females (male-to-female ratio 1:1.51), with a mean age of 57.79 ± 11.38 years (range: 28–77 years), postoperative DVT occurred in 46 patients (8.11%), 36 of whom (78.26%) were diagnosed within 3 days. Thrombosis predominantly affected the muscular veins and posterior tibial veins (91.30%). Multivariate analysis identified a history of thrombosis, injection volume >10 mL of foam, and injection sites distal to the ankle joint as independent risk factors for DVT. Furthermore, Group A demonstrated a significantly lower prevalence of thrombosis at each time point compared to Group B ( p < .05). Conclusion: The incidence of postoperative DVT following combined RFA and foam sclerotherapy for varicose veins is relatively high, with the majority occurring in the early postoperative period. Thrombosis primarily affects the muscular and posterior tibial veins. A history of thrombosis, injection volume >10 mL of foam, and injection sites distal to the ankle joint are independent risk factors. Prophylactic-dose anticoagulation therapy may facilitate thrombus resolution in patients with distal DVT.
8 May 2025 in Phlebology: The Journal of Venous Disease
Objective: The incidence, risk factors, and clinical presentation of deep venous thrombosis (DVT) vary with age. This study aimed to evaluate the differences in clinical characteristics of DVT among patients of different ages. Methods: We retrospectively analyzed 938 patients with symptomatic lower extremity DVT admitted to our hospital between January 2020 and January 2024. Patients were categorized into youth (65 years) groups. Demographic data, comorbidities, risk factors, clinical presentations, and management approaches were collected and analyzed. Results: Most participants were middle-aged or elderly, with young patients constituting only 11.19% of the study population. The youth group had a slight female predominance, while the middle-aged and elderly group had a balanced gender distribution. The elderly group were more likely to have comorbidities such as diabetes and malignancies, though they had a lower prevalence of autoimmune diseases compared to younger patients. Congenital risk factors were relatively rare in the overall population, yet were present in 22.86% of young patients, a significantly higher proportion than in the middle-aged and elderly groups. Most patients with DVT were provoked, especially in the elderly group. The prevalence of concurrent congenital and acquired factors was 13.33% in the youth group, compared to only 4.97% in the middle-aged group and 2.88% in the elderly group. Proximal DVT was most frequent in middle-aged patients, while young patients were more likely to seek treatment in the acute phase and undergo surgical intervention. Anticoagulation noncompliance was noted in nearly 40% of elderly patients but only 6.67% of young patients. Conclusion: Risk factors and clinical characteristics of DVT vary significantly with age, particularly between young and elderly patients. Young patients were more inclined to seek prompt and effective treatment and demonstrated better adherence to anticoagulation therapy.
Introduction: This study aimed to evaluate the clinical efficacy of endovenous treatment (ET) via the profunda femoral vein (PFV) approach for iliofemoral venous obstruction with inadequate femoral vein (FV) inflow in patients with severe postthrombotic syndrome (PTS). Methods: A retrospective analysis included 32 patients who underwent this procedure between January 2021 and January 2023. Clinical symptoms were evaluated using the Villalta score and Venous Clinical Severity Score (VCSS) at baseline, 1 year, and 2 years. Patency rates were determined by duplex ultrasonography. Univariate logistic regression analysis was used to identify risk factors for in-stent restenosis (ISR). Results: The mean age of the patients was 65.5 ± 8.9 years, and 56.3% were men. Among 32 patients, technical success was achieved in all cases (100%). Postoperative in-stent thrombosis occurred in 18.8% (6/32) of patients. Kaplan–Meier analysis revealed primary patency rates of 100% ± 0%, 96.9% ± 3.1%, 93.8% ± 4.2%, 87.5% ± 5.9%, and 65.6% ± 8.4% at 1, 3, 6, 12, and 24 months, respectively. ISR developed in 11 patients, all of whom underwent reintervention, yielding a secondary patency rate of 87.5% ± 5.9% at 2 years. Baseline Villalta scores (17.4 ± 5.5) and VCSS (13.2 ± 2.5) significantly decreased to 6.5 ± 3.0 and 5.1 ± 1.8 at 2 years postoperatively (both p < 0.05). Anticoagulation noncompliance and history of iliofemoral deep vein thrombosis (DVT) were independent predictors of ISR. Conclusion: ET via the PFV approach is a safe and effective option for iliofemoral venous obstruction with inadequate FV inflow in severe PTS, providing favorable patency rates and significant symptom relief. Anticoagulation noncompliance and history of iliofemoral DVT are key factors for ISR.